Jazz Pharmaceuticals (JAZZ) Q4 2025 Earnings
Reported Feb 24, 2026 at 4:07 PM ET · SEC Source
Q4 25 EPS
$6.64
BEAT +2.05%
Est. $6.51
Q4 25 Revenue
$1.20B
BEAT +2.81%
Est. $1.17B
vs S&P Since Q4 25
+26.6%
BEATING MARKET
JAZZ +33.6% vs S&P +6.9%
Full Year 2025 Results
FY 25 EPS
$8.38
FY 25 Revenue
$4.27B
Market Reaction
Did JAZZ Beat Earnings? Q4 2025 Results
Jazz Pharmaceuticals closed out fiscal 2025 on a strong note, posting fourth-quarter adjusted earnings of $6.64 per diluted share, ahead of the $6.51 consensus estimate by 2.05%, while revenue of $1.20 billion beat expectations by 2.81% and rose 10.1… Read more Jazz Pharmaceuticals closed out fiscal 2025 on a strong note, posting fourth-quarter adjusted earnings of $6.64 per diluted share, ahead of the $6.51 consensus estimate by 2.05%, while revenue of $1.20 billion beat expectations by 2.81% and rose 10.1% year over year. The neuroscience franchise did much of the heavy lifting, with Xywav generating $465.45 million in Q4 net product sales, up 16% from a year earlier, and Epidiolex contributing $287.12 million as the epilepsy therapy crossed $1.00 billion in annual sales. Oncology also contributed meaningfully, with newly launched Modeyso delivering $36.54 million in its first full quarter on market following its August 2025 FDA approval. GAAP results were weighed down by $947.86 million in acquired in-process R&D charges, primarily tied to the Chimerix acquisition, driving a full-year net loss of $356.15 million despite the solid top-line momentum. Analysts tracking the stock have noted the company's debt load as a watch item. Looking ahead, Jazz guided 2026 revenues of $4.25 billion to $4.50 billion, with a potential zanidatamab launch in gastroesophageal adenocarcinoma anticipated in the second half of next year.
Key Takeaways
- • Xywav net product sales grew 16% YoY in Q4 to $465 million driven by strong new patient growth with approximately 500 net patient adds in Q4
- • Epidiolex/Epidyolex surpassed $1 billion in annual sales with 9% YoY growth
- • Successful Modeyso launch generating $37 million in first full quarter on market
- • Zepzelca net product sales increased 15% YoY in Q4 to $90 million
- • Approximately 16,175 active Xywav patients exiting Q4, comprising ~10,950 narcolepsy and ~5,225 IH patients
JAZZ YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
JAZZ Revenue by Segment
With YoY comparisons, source: SEC Filings
“2025 was an exceptional year for Jazz, representing our 21st consecutive year of top-line growth and underscoring our commitment to operational excellence as we deliver meaningful innovation for patients.”
— Renee Gala, Q4 2025 Earnings Press Release
JAZZ Earnings Trends
JAZZ vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
JAZZ EPS Trend
Earnings per share: estimate vs actual
JAZZ Revenue Trend
Quarterly revenue: estimate vs actual
JAZZ Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $4.66 | $6.34 | +36.18% | $1.07B | +9.18% |
| Q4 25 BEAT FY | $6.51 | $6.64 | +2.05% | $1.20B | +2.81% |
| FY Full Year | — | $8.38 | — | $4.27B | — |
| Q3 25 BEAT | $5.85 | $8.13 | +38.97% | $1.13B | +1.58% |
| Q2 25 MISS | $-6.25 | $-8.25 | -32.07% | $1.05B | -0.14% |